Benitec Biopharma Inc. (BNTC)

$8.33 2.21% $0.18 Healthcare

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

$84.02M

Dr. Jerel A. Banks M.D., Ph.D.

18.00

Hayward, CA

Jul 11, 2012

-0.87

$-9.60

4.12

4.18

-166,861.54%

-0.98

-0.02

1.85

6,323.21

4.18

-144.62%

-175.36%

Similar stocks (8)

Capricor Therapeutics, Inc.

CAPR

$4.42 -3.73%
Downtrend

Aileron Therapeutics, Inc.

ALRN

$2.85 4.01%
Downtrend

NextCure, Inc.

NXTC

$1.29 -7.86%
Downtrend

Virios Therapeutics, Inc.

VIRI

$0.19 0.05%
Downtrend

Bio-Path Holdings, Inc.

BPTH

$1.02 -0.59%
Downtrend

ZyVersa Therapeutics, Inc.

ZVSA

$2.37 8.71%
Downtrend

eFFECTOR Therapeutics, Inc.

EFTR

$0.05 18.75%
Downtrend

ETF Exposure (4)

Simplify Health Care ETF

PINK

0.42962599999999995%

$33.08 0.33%
Uptrend

iShares Micro-Cap ETF

IWC

0.00569%

$122.48 -0.42%
Uptrend

Vanguard Extended Market Index Fund Institutional Shares

VIEIX

0%

$134.52 1.86%
Uptrend

Vanguard Extended Market Index Fund

VXF

0%

$178.21 0.46%
Uptrend